Bionano Genomics Inc
BNGO3.049USD
+0.099+3.35%
Market hours （ET）Quotes delayed by 15 min
9.46MMarket Cap
LossP/E TTM
More Details of Bionano Genomics Inc Company
Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
Company Info
Ticker SymbolBNGO
Company nameBionano Genomics Inc
IPO dateAug 01, 2018
CEODr. R. Erik Holmlin, Ph.D.
Number of employees98
Security typeOrdinary Share
Fiscal year-endAug 01
Address9540 Towne Centre Drive
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92121
Phone18588887600
Websitehttps://bionano.com/
Ticker SymbolBNGO
IPO dateAug 01, 2018
CEODr. R. Erik Holmlin, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Oldakowski
Mr. Mark Oldakowski
Chief Operating Officer
Chief Operating Officer
441.00
-5.77%
Mark Adamchak
Mark Adamchak
Vice President - Accounting, Principal Accounting Officer
Vice President - Accounting, Principal Accounting Officer
264.00
-2.58%
Ms. Hannah Mamuszka
Ms. Hannah Mamuszka
Independent Director
Independent Director
109.00
-0.91%
Dr. David L. Barker, Ph.D.
Dr. David L. Barker, Ph.D.
Independent Director
Independent Director
97.00
--
Mr. Christopher J. Twomey, CPA
Mr. Christopher J. Twomey, CPA
Independent Director
Independent Director
17.00
-84.26%
Dr. R. Erik Holmlin, Ph.D.
Dr. R. Erik Holmlin, Ph.D.
President, Chief Executive Officer, Principal Financial Officer, Director
President, Chief Executive Officer, Principal Financial Officer, Director
--
--
Mr. David Holmes
Mr. David Holmes
Investor Relations Officer
Investor Relations Officer
--
--
Dr. Yvonne Linney, Ph.D.
Dr. Yvonne Linney, Ph.D.
Independent Director
Independent Director
--
--
Dr. Aleksandar Rajkovic, M.D., Ph.D.
Dr. Aleksandar Rajkovic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Albert A. Luderer, Ph.D.
Dr. Albert A. Luderer, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Oldakowski
Mr. Mark Oldakowski
Chief Operating Officer
Chief Operating Officer
441.00
-5.77%
Mark Adamchak
Mark Adamchak
Vice President - Accounting, Principal Accounting Officer
Vice President - Accounting, Principal Accounting Officer
264.00
-2.58%
Ms. Hannah Mamuszka
Ms. Hannah Mamuszka
Independent Director
Independent Director
109.00
-0.91%
Dr. David L. Barker, Ph.D.
Dr. David L. Barker, Ph.D.
Independent Director
Independent Director
97.00
--
Mr. Christopher J. Twomey, CPA
Mr. Christopher J. Twomey, CPA
Independent Director
Independent Director
17.00
-84.26%
Dr. R. Erik Holmlin, Ph.D.
Dr. R. Erik Holmlin, Ph.D.
President, Chief Executive Officer, Principal Financial Officer, Director
President, Chief Executive Officer, Principal Financial Officer, Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Consumables
3.25M
50.29%
Software
2.07M
32.03%
Instruments
689.00K
10.67%
Services and other
453.00K
7.02%
By RegionUSD
Name
Revenue
Proportion
EMEIA
3.07M
47.48%
Americas
3.06M
47.36%
Asia Pacific
333.00K
5.16%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
3.25M
50.29%
Software
2.07M
32.03%
Instruments
689.00K
10.67%
Services and other
453.00K
7.02%
Shareholding Stats
Updated: Thu, Jul 24
Updated: Thu, Jul 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Heights Capital Management, Inc.
4.69%
The Vanguard Group, Inc.
1.49%
Everstar Asset Management LLC
1.34%
GSA Capital Partners LLP
1.19%
Geode Capital Management, L.L.C.
0.46%
Other
90.83%
Shareholders
Shareholders
Proportion
Heights Capital Management, Inc.
4.69%
The Vanguard Group, Inc.
1.49%
Everstar Asset Management LLC
1.34%
GSA Capital Partners LLP
1.19%
Geode Capital Management, L.L.C.
0.46%
Other
90.83%
Shareholder Types
Shareholders
Proportion
Investment Advisor
8.32%
Hedge Fund
1.19%
Investment Advisor/Hedge Fund
0.47%
Research Firm
0.33%
Individual Investor
0.06%
Bank and Trust
0.02%
Other
89.62%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
193
349.15K
10.38%
-67.10K
2025Q1
262
309.73K
9.24%
-123.47K
2024Q4
284
105.26K
3.91%
-124.97K
2024Q3
298
94.17K
6.55%
-135.04K
2024Q2
310
116.15K
9.81%
-164.95K
2024Q1
318
86.19K
9.42%
-64.99K
2023Q4
324
107.44K
14.24%
-23.70K
2023Q3
345
94.81K
16.11%
-27.58K
2023Q2
356
93.86K
18.29%
-63.50K
2023Q1
366
141.65K
27.72%
-15.82K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Heights Capital Management, Inc.
157.93K
4.69%
-20.40K
-11.44%
Mar 31, 2025
The Vanguard Group, Inc.
49.98K
1.49%
+18.64K
+59.50%
Mar 31, 2025
Everstar Asset Management LLC
44.98K
1.34%
+44.98K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
15.51K
0.46%
-1.12K
-6.75%
Mar 31, 2025
Parametric Portfolio Associates LLC
11.49K
0.34%
+11.49K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.10K
0.3%
-4.00
-0.04%
Mar 31, 2025
BofA Global Research (US)
8.39K
0.25%
+8.37K
+41865.00%
Mar 31, 2025
Osaic Holdings, Inc.
3.21K
0.1%
+3.03K
+1722.73%
Mar 31, 2025
UBS Financial Services, Inc.
1.91K
0.06%
-22.00
-1.14%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Dimensional US Core Equity 1 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR S&P Kensho New Economies Composite ETF
0%
Global X Genomics & Biotechnology ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
Global X HealthTech ETF
0%
Dimensional US Core Equity 1 ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
SPDR S&P Kensho New Economies Composite ETF
Proportion0%
Global X Genomics & Biotechnology ETF
Proportion0%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Genomics Immunology and Healthcare ETF
Proportion0%
Global X HealthTech ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 22, 2025
Merger
60<1
Jan 22, 2025
Merger
60<1
Jan 22, 2025
Merger
60<1
Jan 22, 2025
Merger
60<1
Aug 04, 2023
Merger
10<1
Aug 04, 2023
Merger
10<1
Date
Type
Ratio
Jan 22, 2025
Merger
60<1
Jan 22, 2025
Merger
60<1
Jan 22, 2025
Merger
60<1
Jan 22, 2025
Merger
60<1
Aug 04, 2023
Merger
10<1
Aug 04, 2023
Merger
10<1
Aug 04, 2023
Merger
10<1
Aug 04, 2023
Merger
10<1
